杰德生物科技
JBIO
13.47
-0.29
-2.11%
杰德生物科技
US · JBIO
#3338 按市值排名
上市于 2021
13.47
-0.29
-2.11%
实时 - 追踪5344个代码 - 心跳于446秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
增持
- 机构持股总比例上升了0.3个百分点。
机构持股
- 机构持股比例
- 115.51% +0.31pp
- 机构数量
- 189
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund63.18%
Hedge Fund32.51%
VC/PE Fund16.75%
Public Company2.35%
Private Company0.43%
Individual/Insider0.28%
Government Pension Fund0.17%
Insurance Company0.11%
主要股东 截至 2026-06-30
FMR
14.35% · 9.13M 股
Janus Henderson Group plc
9.86% · 6.27M 股
Fairmount Funds Management LLC
7.16% · 4.55M 股
RA Capital Management, L.P.
5.77% · 3.67M 股
VR Management, LLC
5.06% · 3.22M 股
Paradigm Biocapital Advisors LP
4.89% · 3.11M 股
Bellevue Asset Management AG
4.81% · 3.06M 股
BlackRock
4.40% · 2.80M 股
Franklin Resources
4.39% · 2.79M 股
Vanguard Capital Management, LLC
4.01% · 2.55M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪41份申报 · 23次买入 · 6次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Andrew King | Chief Scientific Officer & Head of R&D | 0.21% |
| Lawrence Klein | Director | 0.05% |
| Tom Frohlich | Chief Executive Officer | 0.01% |
| Eric Dobmeier | Chairperson | -- |
| Tomas Kiselak | Director | -- |
| Christopher Cain | Director | -- |
| Fairmount Funds Management LLC | -- | -- |
| Erin Lavelle | Director | -- |
| Fairmount Healthcare Fund II L.P. | -- | -- |
| Bradford Dahms | Chief Financial Officer | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-06-24 | Mark Eisner | Director | Other Derivative Acquisition | +47,675 | $21.81 |
| 2026-06-08 | Eric Dobmeier | Chairperson | Other Derivative Acquisition | +34,843 | $15.22 |
| 2026-06-08 | Christopher Cain | Director | Other Derivative Acquisition | +34,843 | $15.22 |
| 2026-06-08 | Erin Lavelle | Director | Other Derivative Acquisition | +34,843 | $15.22 |
| 2026-06-08 | Lawrence Klein | Director | Other Derivative Acquisition | +34,843 | $15.22 |
| 2026-06-08 | Peter Harwin | -- | Other Derivative Acquisition | +34,843 | $15.22 |
| 2026-02-11 | Tom Frohlich | Chief Executive Officer | Other Acquisition | +78,750 | -- |
| 2026-02-11 | Tom Frohlich | Chief Executive Officer | Other Derivative Acquisition | +472,500 | $14.81 |
| 2026-02-11 | Bradford Dahms | Chief Financial Officer | Other Acquisition | +37,813 | -- |
| 2026-02-11 | Bradford Dahms | Chief Financial Officer | Other Derivative Acquisition | +226,875 | $14.81 |
| 2026-02-11 | Andrew King | Chief Scientific Officer & Head of R&D | Other Acquisition | +41,250 | -- |
| 2026-02-11 | Andrew King | Chief Scientific Officer & Head of R&D | Other Derivative Acquisition | +247,500 | $14.81 |
| 2026-02-11 | Elizabeth Bekiroglu | -- | Other Acquisition | +28,125 | -- |
| 2026-02-11 | Elizabeth Bekiroglu | -- | Other Derivative Acquisition | +168,750 | $14.81 |
| 2025-10-05 | Fairmount Funds Management LLC | -- | Private Acquisition | +1,333,126 | $9.14 |
| 2025-10-05 | Fairmount Funds Management LLC | -- | Other Derivative Acquisition | +855,047 | $0.00 |
| 2025-07-13 | Bradford Dahms | Chief Financial Officer | Other Derivative Acquisition | +526,000 | $9.00 |
| 2025-06-24 | Atlas Venture Advisors, Inc. | -- | Intent to Sell (Form 144) | -28,977 | $10.48 |
| 2025-06-24 | Atlas Venture Advisors, Inc. | -- | Intent to Sell (Form 144) | -235 | $10.48 |
| 2025-06-23 | Atlas Venture Advisors, Inc. | -- | Intent to Sell (Form 144) | -16,132 | $9.87 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
杰德生物科技 讨论区 0 条评论